Cohort information

ITALY				WP4
Organization		University of Bologna
Name of cohort		CONTRAST (HIV)
Referring partner		UNIBO
Cohort Information	Country(-ies), cities, regions or centers involved	Bologna, Italy
	Time of data collection	03/2021	Ongoing
	Enrolment	Inactive
	Study setting	Single center
Population	Age	Adults,Elderly
	Type	Prospective
	Total number of patients	436
	Type of frailty (WP4)	HIV
Data collection	Clinical data	True
	Serological data	True
	Genetic data	False
	Sample collection	True
	Sample collected	Whole blood	Yes
		PBMC	No
		Dry-spot blood	No
		Plasma	No
		Serum	Yes
		Stool	No
		NP swabs	Yes
		Other	Peripheral blood mononuclear cells
Description	UNIBO will participate in the recruitment of the following SARS-CoV-2 and non-SARS-CoV-2 fragile populations: HIV positive, solid organ transplant recipients, hematopoietic stem cell transplant recipients and solid cancer. CONTRAST is an observational cohort study, with a retrospective phase (2015-2020) and a prospective phase (2021-2025) with a minimum follow-up expected for each patient of 1 year. Patients will be studied longitudinally to define the ""net state of immunosuppression"" of each patient to be correlated with the prevalence of SARS-CoV-2 infection, the course of infection in the short, medium and long term, and the immune response to following a SARS-CoV-2 infection or vaccine.
Publications	- SARS-CoV-2 mRNA Vaccine Response in People Living with HIV According to CD4 Count and CD4/CD8 Ratio [Vaccines]